Skip Navigation


NDT Plus Advance Access originally published online on March 1, 2008
NDT Plus 2008 1(3):148-150; doi:10.1093/ndtplus/sfn018
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
1/3/148    most recent
sfn018v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Cozzolino, M.
Right arrow Articles by Brancaccio, D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2008]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Successful use of low-dose intravenous paricalcitol in the treatment of severe secondary hyperparathyroidism in a haemodialysis patient

Mario Cozzolino, Andrea Galassi, Maurizio Gallieni and Diego Brancaccio

Chair and Division of Nephrology, University of Milan, S Paolo Hospital, Milan, Italy

Correspondence: Mario Cozzolino, Renal Division, S. Paolo Hospital, University of Milan, Via A. di Rudinì, 8-20142, Milan, Italy. Tel: +02-81844381; Fax: +02-89129989; E-mail: mariocozzolino@hotmail.com

Key Words: calcium • dialysis • paricalcitol • PTH • phosphorus

Received for publication November 22, 2007. Accepted for publication January 30, 2008.

The first 10% of the full text of this article appears below.


   Introduction
 
Haemodialysis (HD) patients are commonly affected by secondary hyperparathyroidism (SHPT), hyperphosphataemia and calcitriol deficiency [1]. Classically, serum high PTH levels cause bone-associated diseases, such as osteitis fibrosa and renal osteodystrophy. More recently, the link between SHPT and a systemic toxicity has been elucidated, with SHPT playing a major role in determining cardiovascular disease, including vascular calcification [2,3].

Treatment with calcitriol, the active form of vitamin D, reduces serum PTH levels, but may result in elevations in serum calcium (Ca), phosphorus (P) and Ca x P product levels, increasing the risk of cardiovascular calcification in the HD population [4]. Several new vitamin D analogues have . . . [Full Text of this Article]


   Case report
 

   Discussion
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?